Baxter International says that a Phase I/II study of its bird flu vaccine demonstrates an immune response at low levels and is capable of cross immunization against several strains. Researchers said that they will now launch a Phase III trial in Europe to gauge the vaccine's effectiveness in a large group of healthy volunteers. Data is expected from the late-stage trial by the end of this year.
- read the MarketWatch report
ALSO: MedImmune has licensed its IP on reverse genetics to Sanofi-pasteur for use in developing a pandemic flu vaccine. Report